RecruitingPhase 1NCT05859074
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Studying Angiosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Lara Dunn, MDMemorial Sloan Kettering Cancer Center
- Intervention
- MQ719(biological)
- Enrollment
- 56 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (7)
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05859074 on ClinicalTrials.govOther trials for Angiosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS
- RECRUITINGPHASE2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPHASE2NCT06673628Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsNational Cancer Center, Japan
- RECRUITINGPHASE1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc.
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group
- RECRUITINGNCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver CancersFederation Francophone de Cancerologie Digestive